Cromolyn

Cromolyn

SCHEMBL8199

O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1.[NaH]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 3/20 0.97
LMNA P02545 1/20 0.97
TDP1 Q9NUW8 1/20 0.97
MEN1 O00255 3/20 0.76
KMT2A Q03164 3/20 0.76
HIF1A Q16665 1/20 0.76
ABCG2 Q9UNQ0 9/20 0.47
ABCB1 P08183 2/20 0.47
KDM4E B2RXH2 2/20 0.47
USP2 O75604 2/20 0.47
CSNK2A2 P19784 1/20 0.47
PTGS1 P23219 1/20 0.47
CSNK2B P67870 1/20 0.47
CSNK2A1 P68400 1/20 0.47
CSNK2A3 Q8NEV1 1/20 0.47
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
ADRB2 P07550 2/20 0.43
NMT2 O60551 1/20 0.43
ADRB1 P08588 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cromolyn SCHEMBL318268 1.00 GPR35 (0.97) GPR35LMNATDP1MEN1KMT2A
Cromolyn SCHEMBL29352570 0.99 GPR35 (1.00) GPR35LMNATDP1MEN1KMT2A
Cromolyn SCHEMBL3865 0.99 GPR35 (1.00) GPR35LMNATDP1MEN1KMT2A
Cromolyn SCHEMBL29353205 0.99 GPR35 (1.00) GPR35LMNATDP1MEN1KMT2A
Cromolyn SCHEMBL8662365 0.97 GPR35 (0.97) GPR35LMNATDP1MEN1KMT2A
Cromolyn SCHEMBL4108171 0.97 GPR35 (0.97) GPR35LMNATDP1MEN1KMT2A
SCHEMBL11253121 0.95 GPR35 (0.93) GPR35LMNATDP1MEN1KMT2A
SCHEMBL2717434 0.93 GPR35 (0.88) GPR35LMNATDP1MEN1KMT2A
SCHEMBL11175797 0.93 GPR35 (0.88) GPR35LMNATDP1MEN1KMT2A
SCHEMBL11832140 0.93 GPR35 (0.88) GPR35LMNATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 15841 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747263-A1 LIPID NANOPARTICLES AND USES THEREOF University of Connecticut (US) 2026-05-27 EP claimed
US-12616803-B2 Apparatus for dispensing inhalant medicament METOPI PHARMACEUTICALS, INC. (US) 2026-05-05 US claimed
WO-2026090557-A1 SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA TELIOS PHARMA INC. (US) 2026-04-30 WO claimed
US-20260108514-A1 METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2026-04-23 US claimed
US-12605471-B2 Cromolyn derivatives and related methods of imaging and treatment THE GENERAL HOSPITAL CORPORATION (US) 2026-04-21 US claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
EP-4687912-A1 GENOTYPE-SPECIFIC METHODS AND SYSTEMS FOR TREATMENT OF NEURODEGENERATIVE DISEASE Phenonet, Inc. (US) 2026-02-11 EP claimed
US-12545948-B2 Identification of novel loci in asthma and methods of use thereof for the diagnosis and treatment of asthma THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2026-02-10 US claimed
US-20260026967-A1 MATERIALS AND METHODS FOR PUNCTAL PLUGS GLAUKOS CORP (US) 2026-01-29 US claimed
EP-4676500-A2 MICROBIAL CONSORTIA Kanvas Biosciences, Inc (US) 2026-01-14 EP claimed
WO-1990006775-A1 A NOVEL NONPHOSPHOLIPID LIPOSOME COMPOSITION FOR SUSTAINED RELEASE OF DRUGS LIPOSOME TECHNOLOGY, INC. (US) 1990-06-28 WO claimed
US-4895719-A SUSPENSION, ENCAPSULATION, DRUG DELIVERY LIPOSOME TECHNOLOGY, INC. (US) 1990-01-23 US claimed
US-4882170-A Method of treatment FISONS CORPORATION (US) 1989-11-21 US claimed
EP-0223831-A4 LIPOSOME INHALATION METHOD AND SYSTEM. LIPOSOME TECHNOLOGY INC (US) 1987-10-12 EP claimed
EP-0223831-A1 LIPOSOME INHALATION METHOD AND SYSTEM. LIPOSOME TECHNOLOGY INC (US) 1987-06-03 EP claimed
WO-1986006959-A1 LIPOSOME INHALATION METHOD AND SYSTEM LIPOSOME TECHNOLOGY, INC. (US) 1986-12-04 WO claimed
EP-0036145-B1 AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT INTERx RESEARCH CORPORATION (US) 1985-05-29 EP claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
US-4269835-A Nasal composition for relieving nasal distress WHITTLE BARRY J 1981-05-26 US claimed
US-4161516-A PELLET OR GRANULAR, ADAPTED TO BE FLUIDIZE AND USED AS INHALANT FISONS LIMITED (GB) 1979-07-17 US claimed